Agency seeks comment, at May 31 public hearing and docket open through July 2, on health and safety risks, manufacturing and product quality and marketing/labeling/sales around allowing cannabis-derived ingredients non-drug products. It wants input from across sectors of stakeholders, including opponents as well as proponents of allowing cannabis-derived ingredients in any category of regulated products other than drugs.
Allowing cannabis-derived ingredients' use in any non-drug product available in the US allows "criminals" in "the marijuana industry" to profit, the Food and Drug Administration heard from speakers at a 31 May public hearing.
On the other hand, speakers during the agency's first-ever hearing on the use of cannabis-derived ingredients in products subject to...